Ken Griffin Stock Portfolio: Top 5 Stock Picks

Page 1 of 5

In this article, we discuss the top 5 stock picks of Ken Griffin. If you want to see more stocks in this selection, check out Ken Griffin Stock Portfolio: Top 10 Stock Picks

5. Boston Scientific Corporation (NYSE:BSX)

Number of Hedge Fund Holders: 53

Citadel Investment Group’s Stake Value: $561,256,000

Boston Scientific Corporation (NYSE:BSX) is a Massachusetts-based company that develops, manufactures, and markets medical devices for use in interventional medical specialties worldwide. It operates through three segments – MedSurg, Rhythm and Neuro, and Cardiovascular. Ken Griffin raised his stake in Boston Scientific Corporation (NYSE:BSX) by 16% in Q3 2022, holding 14.5 million shares worth $561.25 million, representing 0.12% of the total 13F securities. 

On October 27, Canaccord analyst William Plovanic raised the price target on Boston Scientific Corporation (NYSE:BSX) to $48 from $45 and kept a Buy rating on the shares. The analyst believes his thesis remains intact and thinks the set up for 2023 is resilient given organic growth is very strong and one-time annual impacts in 2022 of higher tax and FX headwinds will not possibly repeat in 2023.

According to Insider Monkey’s data, 53 hedge funds were bullish on Boston Scientific Corporation (NYSE:BSX) at the end of September 2022, compared to 56 funds in the earlier quarter. Andreas Halvorsen’s Viking Global is the leading position holder in the company, with more than 16 million shares worth $626 million. 

Here is what Artisan Partners specifically said about Boston Scientific Corporation (NYSE:BSX) in its Q2 2022 investor letter:

“We took advantage of Boston Scientific Corporation (NYSE:BSX)’s share price pullback during the quarter. We believe the company is well-positioned to benefit from an expected return of elective medical procedures and several innovative product profit cycles in the periods ahead. Meanwhile, the company’s health care end market could prove relatively resilient in a recession scenario.”

Follow Boston Scientific Corp (NYSE:BSX)

Page 1 of 5